Bio Impact Capital LLC Intellia Therapeutics, Inc. Transaction History

Bio Impact Capital LLC

$611 Million
Q1 2024

A detailed history of Bio Impact Capital LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Bio Impact Capital LLC holds 432,598 shares of NTLA stock, worth $9.93 Million. This represents 1.95% of its overall portfolio holdings.

Number of Shares

432,598

Previous 382,598 13.07%

Holding current value

$9.93 Million

Previous $11.7 Million 2.01%

% of portfolio

1.95%

Previous 2.83%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$23.82 - $32.8 $1.19 Million - $1.64 Million	50,000 Added 13.07%	432,598 $11.9 Million
Q4 2023 Feb 13, 2024	SELL	$23.16 - $32.34 $3.75 Million - $5.24 Million	-162,041 Reduced 29.75%	382,598 $11.7 Million
Q2 2023 Aug 14, 2023	SELL	$34.58 - $46.03 $962,015 - $1.28 Million	-27,820 Reduced 4.86%	544,639 $22.2 Million
Q1 2023 May 12, 2023	BUY	$33.3 - $44.82 $3.9 Million - $5.25 Million	117,221 Added 25.75%	572,459 $21.3 Million
Q4 2022 Feb 14, 2023	BUY	$33.21 - $62.69 $2.68 Million - $5.07 Million	80,829 Added 21.59%	455,238 $15.9 Million

Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $4.04 Million - $5.38 Million	75,000 Added 25.05%	374,409 $21 Million
Q2 2022 Aug 11, 2022	BUY	$38.49 - $76.21 $5.39 Million - $10.7 Million	140,000 Added 87.82%	299,409 $15.5 Million
Q1 2022 May 13, 2022	SELL	$58.27 - $118.99 $65,145 - $133,030	-1,118 Reduced 0.7%	159,409 $11.6 Million
Q4 2021 Feb 11, 2022	SELL	$100.76 - $138.36 $210,890 - $289,587	-2,093 Reduced 1.29%	160,527 $19 Million
Q3 2021 Nov 15, 2021	BUY	$132.37 - $176.78 $4.56 Million - $6.09 Million	34,458 Added 26.89%	162,620 $21.8 Million
Q4 2020 Feb 16, 2021	BUY	$18.83 - $63.53 $2.41 Million - $8.14 Million	128,162 New	128,162 $6.97 Million

Others Institutions Holding NTLA

# of Institutions

314

Shares Held

89.3M

Call Options Held

686K

Put Options Held

599K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.74B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bio Impact Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bio Impact Capital LLC with notifications on news.

Account

Bio Impact Capital LLC Intellia Therapeutics, Inc. Transaction History